Seattle Genetics announces ADCETRIS® (Brentuximab Vedotin) approval in Japan
Seattle Genetics announced that its collaborator, Takeda Pharmaceutical, has received approval from the Japanese MHLW for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan. September 21, 2018